CDK 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (mBC): The Likelihood of being Helped or Harmed (LHH) as a patient-centred tool to assess clinical impact and safety

被引：0
|
作者：
Mastrantoni, L. [1 ]
Orlandi, A. [2 ]
Palazzo, A. [2 ]
Garufi, G. [1 ]
Fabi, A. [3 ]
Daniele, G. [4 ]
Giannarelli, D. [5 ]
Tortora, G. [6 ]
Bria, E. [6 ]
机构：
[1] Univ Cattolica Sacro Cuore, Med Oncol Dept, Rome, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Rome, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Women Children & Publ Hlth Sci, Precis Med Breast Unit, Sci Directorate, Rome, Italy
[4] Fdn Policlin Univ Agostino Gemelli IRCCS, UOC Phase I, Rome, Italy
[5] Fdn Policlin Univ Agostino Gemelli IRCCS, Biostat, Rome, Italy
[6] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol Unit, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
234P
引用
收藏
页码：S644 / S644
页数：1
相关论文
共 50 条
  • [21] An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer
    Robert, Marie
    Frenel, Jean-Sebastien
    Bourbouloux, Emmanuelle
    Rigaud, Dominique Berton
    Patsouris, Anne
    Augereau, Paule
    Gourmelon, Carole
    Campone, Mario
    DRUGS, 2018, 78 (13) : 1353 - 1362
  • [22] Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
    George, Mridula A.
    Qureshi, Sadaf
    Omene, Coral
    Toppmeyer, Deborah L.
    Ganesan, Shridar
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [23] Clinical outcomes of CDK4/6 inhibitors in patients with bone only metastatic breast cancer
    Mardani, Mahta
    Noordeen, Suleyman
    Clifton, Katherine
    Ma, Cynthia
    Luo, Jingqin
    Xi, Jing
    Bagegni, Nusayba
    Ademuyiwa, Foluso
    Suresh, Rama
    Frith, Ashley
    Davis, Andrew
    Bose, Ron
    Peterson, Lindsay
    Thomas, Shana
    Tao, Yu
    Kobayashi, Takayuki
    Xiang, Jingyu
    Xu, Yalin
    Su, Xinming
    Weilbaecher, Katherine
    CANCER RESEARCH, 2024, 84 (09)
  • [24] CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Li, Qing
    Razavi, Pedram
    Li, Zhiqiang
    Paula, Arnaud F. Da Cruz
    Brogi, Edi
    Scaltriti, Maurizio
    Reis-Filho, Jorge S.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2019, 79 (13)
  • [25] UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)
    Gullick, G.
    Owen, C.
    Cook, S.
    Helbrow, J.
    Squires, R.
    Reed, H. M.
    Park, S.
    Weir, E.
    Aquilina, F.
    Webber, N.
    Nye, E.
    Atkinson, C.
    Blair, C.
    Halstead, A.
    Daniels, E.
    Alves, A.
    Chew, S.
    Thomas, W.
    Spensley, S.
    Robinson, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S360 - S360
  • [26] CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR plus MBC) with ESR1 mutations and fusions
    Brett, Jamie O.
    Weipert, Caroline M.
    Ritterhouse, Lauren L.
    Zhang, Nicole
    Yu, Junhua
    Ryan, Lianne Y.
    Spring, Laura M.
    Rivera, Miguel N.
    Lennerz, Jochen K.
    Dias-Santagata, Dora
    Ellisen, Leif W.
    Bardia, Aditya
    Wander, Seth A.
    CANCER RESEARCH, 2022, 82 (12)
  • [27] Improving Breast Cancer Therapy With CDK4/6 Inhibitors
    Jaganathan, Hamsa
    Overstreet, Karen
    Reed, Elizabeth
    CLINICAL BREAST CANCER, 2014, 14 (06) : 379 - 380
  • [28] Predicting Response to CDK4/6 Inhibitors in Breast Cancer
    Schultz, Emily
    Hamilton, Deanna
    Wang, Jianxin
    Witkiewicz, Agnieszka
    LABORATORY INVESTIGATION, 2023, 103 (03) : S208 - S208
  • [29] CDK4/6 inhibitors in breast cancer: spotting the difference
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    NATURE MEDICINE, 2021, 27 (11) : 1868 - 1869
  • [30] Safety and efficacy of concomitant RT and CDK4/6 inhibitors in metastatic breast cancer patients.
    Visani, L.
    Saieva, C.
    Desideri, I.
    Scotti, V.
    Dominici, L.
    Scoccimarro, E.
    Aquilano, M.
    Cerbai, C.
    Palmieri, V. E.
    Maragna, V.
    Becherini, C.
    Bernini, M.
    Sanchez, L.
    Orzalesi, L.
    Nori, J.
    Antonuzzo, L.
    Bianchi, S.
    Meattini, I.
    Livi, L.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S495 - S496
12345